Synonyms: CCS-1477 | CCS1477
Compound class:
Synthetic organic
Comment: Inobrodib (CCS1477) is an orally active, potent, and selective inhibitor of the bromodomains of the E1A binding protein p300 and CREB binding protein (CBP) histone acetyltransferases (HATs) [1-2,5].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Inobrodib was progressed to clinical evaluations as a potential treatment for advanced solid tumours [4] and haematological malignancies [3]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03568656 | Study to Evaluate CCS1477 in Advanced Tumours | Phase 1/Phase 2 Interventional | CellCentric Ltd. | ||
NCT04068597 | Study to Evaluate CCS1477 in Haematological Malignancies | Phase 1/Phase 2 Interventional | CellCentric Ltd. |